Recurrent Hematologic Malignancy
9
1
1
4
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 87/100
22.2%
2 terminated out of 9 trials
66.7%
-19.9% vs benchmark
0%
0 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (9)
Mobile Health Application (PACT) to Improve Engagement in Advance Care Planning
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant
Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
Distress Associated with Coronavirus Disease 2019 and Telehealth on Supportive Care Patients with Advanced Cancer
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies
Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant
Fructooligosaccharides in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer